VIM-D salvage chemotherapy in Hodgkin's disease
- Cite this article as:
- Phillips, J.K., Spearing, R.L., Davies, J.M. et al. Cancer Chemother. Pharmacol. (1990) 27: 161. doi:10.1007/BF00689103
- 29 Downloads
A total of 15 patients with relapsed or resistant Hodgkin's disease were treated with a combination of etoposide (VP16), ifosfamide, mitozantrone and dexamethasone (VIM-D). The regime was well tolerated, the only major toxicity being myelosuppression. Complete remissions (CRs) were obtained in 4 patients and were maintained for 2,4, 10 and 14 months, 10 subjects subsequently received an autologous bone marrow transplant with highdose chemotherapy (ABMT). Previous exposure to VIMD did not appear to predict for or prejudice the response to subsequent ABMT.